Evaluation of Continuous Infusion Vancomycin Administration in a Critically Ill Trauma Population

Area of Science:

• Pharmacology
• Critical Care Medicine
• Infectious Diseases

Background:

• Vancomycin is a critical antibiotic for gram-positive infections in trauma ICUs.
• Intermittent vancomycin dosing presents challenges in trough level monitoring and achieving therapeutic targets.
• Optimizing vancomycin delivery is essential for effective infection management and patient outcomes.

Purpose of the Study:

• To compare the time to achieve goal vancomycin levels between continuous infusion and intermittent infusion protocols.
• To evaluate the incidence of target attainment and associated clinical outcomes.
• To assess the impact on monitoring requirements and patient safety.

Main Methods:

• Retrospective cohort study of 150 trauma ICU patients receiving vancomycin for ≥48 hours (July 2011-July 2015).
• Comparison of continuous infusion versus standard intermittent infusion vancomycin dosing strategies.
• Analysis of time to goal vancomycin levels, target attainment rates, blood sample frequency, therapy duration, and nephrotoxicity.

Main Results:

• Continuous infusion vancomycin significantly decreased time to goal levels (2.5 vs 3.8 days) and increased target attainment (60% vs 40%).
• Continuous infusion required fewer blood samples (1 vs 3) and resulted in shorter therapy duration (3.8 vs 6.8 days).
• Nephrotoxicity incidence was lower with continuous infusion (21% vs 43%), and fewer doses were missed.

Conclusions:

• Continuous infusion vancomycin is superior to intermittent dosing in trauma ICUs, achieving therapeutic levels faster and more reliably.
• This approach reduces monitoring burden, shortens treatment duration, and improves patient safety by decreasing nephrotoxicity.
• Further large-scale trials are warranted to confirm these findings and explore cost-effectiveness.